NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Embark Technology, Inc. (“Embark” or the “Company”) (NASDAQ: EMBK). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Embark and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On January 6, 2022, The Bear Cave published a short report entitled “Problems at Embark Technology (EMBK”) (the “Bear Cave Report”). The Bear Cave Report alleged, among other issues, “that Embark appears to lack true economic substance” and that its “current evaluation appears to be based on puffery rather than actual substance”, noting that “[t]he company holds no patents, has only a dozen or so test trucks, and may be more bark than bite.”
On this news, Embark’s stock price fell $1.37 per share, or 16.75%, to close at $6.81 per share on January 6, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
- Cytokinetics Announces Data From REDWOOD-HCM OLE andGALACTIC-HF Presented as Late Breaking Science Presentationsat the European Society of Cardiology Heart Failure 2022 Congress - May 23, 2022
- Genius Brands International Announces its Chairman & CEO Andy Heyward will be Appearing Today on Cheddar - May 23, 2022
- Breast Cancer Diagnostics Market is Estimated to Rise at a CAGR of 7% during the Forecast Period, notes TMR Study - May 23, 2022